Purepac to become Faulding through subsidiary consolidations.

PUREPAC TO MERGE WITH FAULDING U.S. SUBSIDIARIES, CHANGE NAME to Faulding, Inc. in a series of transactions announced Aug. 10. Generic drug maker Purepac, which is 64%-owned by the Australian manufacturer Faulding, has agreed to acquire: Faulding Pharmaceuticals, which is Faulding's U.S. injectables marketing arm; Faulding Medical Devices, which is developing shell glass vial and device technologies; and Faulding Puerto Rico, which owns products and manufacturing facilities in Puerto Rico that formerly belonged to DuPont Merck.

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet